FMP

FMP

Enter

AKRO - Akero Therapeutics, ...

Financial Summary of Akero Therapeutics, Inc.(AKRO), Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in

photo-url-https://financialmodelingprep.com/image-stock/AKRO.png

Akero Therapeutics, Inc.

AKRO

NASDAQ

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

18.32 USD

-0.59 (-3.22%)

About

ceo

Dr. Andrew Cheng M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.akerotx.com

exchange

NASDAQ

Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, I...

CIK

0001744659

ISIN

US00973Y1082

CUSIP

00973Y108

Address

601 Gateway Boulevard

Phone

650 487 6488

Country

US

Employee

58

IPO Date

Jun 20, 2019

Summary

CIK

0001744659

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

00973Y108

ISIN

US00973Y1082

Country

US

Price

18.32

Beta

-0.29

Volume Avg.

1.21M

Market Cap

1.27B

Shares

-

52-Week

11.25-58.38

DCF

3.96

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-5.65

P/B

-

Website

https://www.akerotx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest AKRO News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep